Jaklic B R, Rushin J, Ghosh B C
Department of Surgery, National Naval Medical Center, Bethesda, Maryland 20889-5000, USA.
Ann Surg Oncol. 1995 Sep;2(5):429-34. doi: 10.1007/BF02306376.
Given the higher incidence and better prognosis of thyroid cancers in women, the possibility arises that these lesions may be influenced by sex hormones. With the development of monoclonal antibodies to the estrogen and progesterone receptor proteins, receptor status can now be determined by immunohistochemical methods that allow direct localization of receptors in tissue.
Using this technique, we have studied tissues of 11 patients, 2 of them pregnant, with thyroid lesions. Paraffin-embedded tissues were used. Positive controls consisted of known estrogen- and progesterone-positive breast carcinomas.
Examination of both the thyroid lesions and adjacent uninvolved thyroid tissue showed no nuclear reactivity with either estrogen or progesterone receptor antibodies. Our study did not confirm the previously reported incidence of estrogen and progesterone receptors in thyroid lesions.
We conclude that contrary to earlier indications, estrogen and progesterone receptor proteins are neither significantly detectable nor pertinent for follow-up or prognosis in the patient with thyroid neoplasia.
鉴于甲状腺癌在女性中的发病率较高且预后较好,这些病变可能受性激素影响。随着针对雌激素和孕激素受体蛋白的单克隆抗体的发展,现在可以通过免疫组织化学方法确定受体状态,该方法可直接在组织中定位受体。
使用该技术,我们研究了11例患有甲状腺病变患者的组织,其中2例为孕妇。使用石蜡包埋组织。阳性对照包括已知的雌激素和孕激素阳性乳腺癌。
对甲状腺病变和相邻未受累甲状腺组织的检查均显示,雌激素或孕激素受体抗体均无核反应性。我们的研究未证实先前报道的甲状腺病变中雌激素和孕激素受体的发生率。
我们得出结论,与早期迹象相反,雌激素和孕激素受体蛋白在甲状腺肿瘤患者中既无法显著检测到,也与随访或预后无关。